Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study

The present study aimed at evaluating whether a weekly cisplatin, epirubicin, and paclitaxel (PET) regimen could increase the pathological complete response (pCR) rate in comparison with a tri-weekly epirubicin and paclitaxel administration in locally advanced breast cancer (LABC) patients. Patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Frasci, G, D'Aiuto, G, Comella, P, Thomas, R, Botti, G, Di Bonito, M, De Rosa, V, Iodice, G, Rubulotta, M R, Comella, G
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2006
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360722/
https://ncbi.nlm.nih.gov/pubmed/17047649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603395
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky